Synthesis and pharmacological evaluation of novel selective MOR agonist 6β-pyridinyl amidomorphines exhibiting long-lasting antinociception.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 28603600)

Published in Medchemcomm on October 18, 2016

Authors

Ákos Urai1, András Váradi2, Levente Szőcs1, Balázs Komjáti3, Valerie Le Rouzic2, Amanda Hunkele2, Gavril W Pasternak2, Susruta Majumdar2, Sándor Hosztafi1

Author Affiliations

1: Department of Pharmaceutical Chemistry, Semmelweis University, Hőgyes E. u. 9., Budapest H-1092, Hungary.
2: Molecular Pharmacology and Chemistry Program and Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Ave., New York, NY 10065, USA.
3: Department of Organic Chemistry and Technology, Budapest University of Technology and Economics, Szent Gellért tér 4, Budapest 1111, Hungary.

Articles cited by this

Opioid pharmacology. Pain Physician (2008) 2.12

mu Opioid receptor knockout in mice: effects on ligand-induced analgesia and morphine lethality. Brain Res Mol Brain Res (1998) 1.78

Neurobiology of opiate abuse. Trends Pharmacol Sci (1992) 1.44

Truncated G protein-coupled mu opioid receptor MOR-1 splice variants are targets for highly potent opioid analgesics lacking side effects. Proc Natl Acad Sci U S A (2011) 1.39

Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a Phase III, randomized, double-blind, placebo-controlled study. Nephrol Dial Transplant (2009) 1.31

Design, synthesis, and biological evaluation of 6alpha- and 6beta-N-heterocyclic substituted naltrexamine derivatives as mu opioid receptor selective antagonists. J Med Chem (2009) 1.26

Clocinnamox: a novel, systemically-active, irreversible opioid antagonist. J Pharmacol Exp Ther (1992) 1.11

Determination of receptors that mediate opiate side effects in the mouse. Br J Pharmacol (1983) 1.06

Characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives as novel leads to development of mu opioid receptor selective antagonists. ACS Chem Neurosci (2011) 1.03

Chloroxymorphamine, and opioid receptor site-directed alkylating agent having narcotic agonist activity. Science (1979) 0.98

Synthesis and biological evaluation of alpha- and beta-6-amido derivatives of 17-cyclopropylmethyl-3, 14beta-dihydroxy-4, 5alpha-epoxymorphinan: potential alcohol-cessation agents. J Med Chem (2008) 0.94

Preclinical disposition (in vitro) of novel μ-opioid receptor selective antagonists. Drug Metab Dispos (2011) 0.89

Synthesis and biological evaluation of some 6-arylamidomorphines as analogues of morphine-6-glucuronide. Bioorg Med Chem (2004) 0.87

Pharmacological studies with an alkylating narcotic agonist, chloroxymorphamine, and antagonist, chlornaltrexamine. J Pharmacol Exp Ther (1980) 0.84

Synthesis of Carfentanil Amide Opioids Using the Ugi Multicomponent Reaction. ACS Chem Neurosci (2015) 0.84

Pharmacological characterization of dihydromorphine, 6-acetyldihydromorphine and dihydroheroin analgesia and their differentiation from morphine. Eur J Pharmacol (2004) 0.83

Activity of mu- and delta-selective opioid agonists in the guinea pig ileum preparation: differentiation into peptide and nonpeptide classes with beta-funaltrexamine. J Pharmacol Exp Ther (1986) 0.82

Novel 6β-acylaminomorphinans with analgesic activity. Eur J Med Chem (2013) 0.82

Synthesis and Characterization of a Dual Kappa-Delta Opioid Receptor Agonist Analgesic Blocking Cocaine Reward Behavior. ACS Chem Neurosci (2015) 0.79